Q-omics provides the consensus-scored RMDN1 profile across patient tissues and cancer cell-line models. RMDN1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RMDN1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RMDN1 RNA expression shows 19,140 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, THCA, and ACC as cancer lineages where RMDN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RMDN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RMDN1 survival associations across molecular data types. RMDN1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RMDN1 RNA expression–survival associations across cancer types. High RMDN1 expression shows unfavorable associations in UVM, LGG, HNSC and LUAD, but favorable associations in KIRC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RMDN1 RNA expression.
This table summarizes RMDN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RMDN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RMDN1 shows lower tumor expression in THCA, KICH, KIRP and KIRC and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher RMDN1 RNA expression in normal versus tumor tissue (log2 FC = −1.540, t-test p < 0.001).
This table shows molecular features associated with RMDN1 in patient tissues and cancer cell lines. In patient samples, RMDN1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RMDN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
